Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199206 | 0.87 | CA2 (0.55) | CA2TSHRGABRA1GABRB2ALDH1A1 | |
| Propionaldehyde SCHEMBL28285975 | 0.84 | MEN1 (0.36) | CA2TSHRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL28285972 | 0.83 | CA2 (0.44) | CA2TSHRGABRA1GABRB2MEN1 | |
| SCHEMBL30017938 | 0.81 | PNMT (0.42) | CA2TSHRALDH1A1PNMTCYP1A2 | |
| SCHEMBL16579377 | 0.81 | PNMT (0.42) | CA2TSHRALDH1A1PNMTCYP1A2 | |
| SCHEMBL11788984 | 0.81 | TSHR (0.39) | CA2TSHRALDH1A1PNMTCYP1A2 | |
| SCHEMBL28399443 | 0.81 | TSHR (0.44) | CA2TSHRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL11792315 | 0.81 | TSHR (0.44) | CA2TSHRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL9257718 | 0.81 | P2RX7 (0.41) | CA2TSHRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL19785374 | 0.80 | CA2 (0.48) | CA2TSHRGABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63270632-A | — | — | None | — | — | JP | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| EP-0442115-B1 | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| US-5105036-A | Friedel-Crafts catalyst and oxy-substituted cyclic amidines as cocatylsts; preferential formation of p-isomer | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| EP-0442115-A1 | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1991-08-21 | — | — | EP | disclosed |
| JP-S63270632-A | NOVEL DICHLOROTRIFLUOROMETHYLTOLUENE AND PRODUCTION THEREOF | CENTRAL GLASS CO LTD | 1988-11-08 | — | — | JP | disclosed |
| US-4219570-A | Insect repellents and a method of repelling insects | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | CA2 3057/4885TSHR 4759/4885GABRA1 4178/4885 |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | CA2 3057/4885TSHR 4759/4885GABRA1 4178/4885 |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | CA2 2420/4885TSHR 3748/4885GABRA1 4233/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | CA2 4153/4885TSHR 216/4885GABRA1 80/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | CA2 1575/4885TSHR 97/4885GABRA1 108/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | CA2 1692/4885TSHR 3807/4885GABRA1 4282/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CA2 4029/4885TSHR 909/4885GABRA1 764/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | CA2 478/4885TSHR 11/4885GABRA1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.